Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (14892)	2/13/1998 12:27:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 32384

AH; Right you are; I did misconstrue your post, but my statement of clinical trial testing is still valid. The people who have responded to my post (thanks guys) feel that phase 1 testing for breast cancer is unnecessary but I still feel that not to do so may be taking unwarranted risk if they do not get prior FDA approval. The previous phase 1 testing may simply have a different target population; eg prostate cancer patients are all male and are treated differently than female breast cancer patients. Although phase 1 testing is usually done in healthy subjects, the subjects can be from different target populations and therefore results from phase 1 tests from one target population cannot automatically be generalized to another target population. Does anyone think that phase 1 testing in, say, adult males is transferable to females of child bearing potential? To do so without FDA approval runs unwarranted risks imo. Company IR statements about considering phase II options are ambiguous and leave the company lots of wiggle room; it is positive spin intended to encourage investors imo, but doesn't really commit the company. I hope this clarifies my point which I still think is valid, whatever Ligand ultimately does. David PS Unfortunately this thread is now full of hundreds of postings which make it impossible for me to completely follow and still leave the rest of my investing activities (not to mention my life) intact.